Hormonal
Metformin is the first-line therapy for Type 2 Diabetes, improving glycemic control, increasing insulin sensitivity, and reducing cardiovascular risk and mortality.
Metformin is the standard first-line medication for Type 2 Diabetes. It helps lower blood sugar, improves how your body uses insulin, and uniquely protects your heart and blood vessels, potentially extending your life. It is generally well-tolerated, though some people experience stomach upset initially. It is not suitable for those with significant kidney problems.
Metformin has been proven to be efficacious in lowering blood glucose, increasing insulin sensitivity, reducing cardiovascular [92] and hypoglycemia risk [93], and is the only hypoglycemic agent to improve macrovascular outcomes [94] and to reduce mortality rates in T2DM patients [95].
Why this rating
Cited as a major class with proven efficacy, multiple benefits, and mortality reduction based on extensive clinical use.
Source
Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention
Yanling Wu et al. · International Journal of Medical Sciences · 2014
DOI 10.7150/ijms.10001
More from this paper
- Obesity is the most important modifiable risk factor for Type 2 Diabetes, influencing insulin resistance and disease progression.Strong
- SGLT2 inhibitors (e.g., Dapagliflozin) lower blood glucose by preventing renal glucose reabsorption, resulting in reduced HbA1c, fasting plasma glucose, blood pressure, and body weight.Good
- GLP-1 receptor agonists (e.g., Exenatide, Liraglutide, Lixisenatide) lower HbA1c, promote weight loss, and reduce hypoglycemia risk by stimulating insulin secretion and increasing satiety.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →